# Immunocan

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunocan

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $37M
- Latest round: Series A (May 13, 2026)
- Investors on record: 4

## About

Established in 2020 and based in Shanghai, China, Shanghai Immunocan Biotechnology Co., Ltd., trading as Immunocan, is a biotech company that focuses on creating a new antibody drug platform. In May 2026, Immunocan raised CNY 250 million in series A funding led by Vivo Capital, with participation fromEssential Capital, and Kingray Capital, TigerYeah Capital.

The company engages in creating a new antibody drug platform. The company's gene editing and replacement technology can replace several Mb-level DNA fragments at a time. The company is developing antibody drugs for cancer patients.

The company's revenue is generated by creating a new antibody drug platform.

The series A round of financing will be primarily used to accelerate the ongoing research and development of the gene-edited animal platform, the commercialization of the fully human antibody rabbit platform, the construction of the AI ??antibody drug screening platform, the development of backbone antibodies for complex targets, and the company's daily operations and team expansion.

## Funding rounds

- Series A, May 13, 2026, $37M — Vivo Capital, Essential Capital, TigerYeah Capital, Kingray Capital

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- Essential Capital — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Kingray Capital (https://capitalatlas.ai/funds/kingray-capital) — Series A